The Distal Dilemma: Why Four Trials Failed — and What ORIENTAL MEVO Got Right

A 62-year-old woman arrives with sudden dense aphasia and right arm weakness. NIHSS 10. CT angiogram shows isolated distal M2 occlusion. Thrombolysis window missed by 30 minutes. Two years ago your neurointerventionalist was already threading a catheter. Today, four randomized trials later, you watch and wait.

This is the clinical paralysis that ESCAPE-MeVO, DISTAL, DISCOUNT, and DUSK left behind — and the reality that new trials are beginning to undo. Between 2024 and early 2025, four trials delivered what appeared to be a definitive verdict: thrombectomy for medium and distal vessel occlusions (MeVO/DVO) doesn't work. Emergency departments adjusted practice accordingly. But the problem wasn't that reperfusion biology changes with vessel size. The problem was who got enrolled.

The diagnosis drives the treatment — so let's get the diagnosis right. The real question isn't whether distal vessels should be opened. It's which patients benefit from opening them, and with what technology. Four trials gave us one answer. Two emerging trials are giving us another. The difference lies in understanding what went wrong.

The Rise: LVO Thrombectomy and the Extrapolation Temptation (2015–2023)

In 2015, five landmark trials — MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, and REVASCAT — established mechanical thrombectomy for large vessel occlusion as standard of care. The numbers were transformative: NNT of 5 for functional independence, absolute risk reductions approaching 20%, effect sizes rarely seen in acute neurology. The target was clear: internal carotid artery and M1 segment occlusions.

The extrapolation seemed obvious. If we can open M1, why not M2? Why not M3, A2, P2? The ischemic penumbra doesn't know which arterial branch supplies it. Tissue at risk is tissue at risk.

Observational data supported the logic. Single-center series showed recanalization rates in distal vessels approaching those in proximal targets — 80% or higher in experienced hands. Complication rates were low. Symptomatic hemorrhage rates remained in the 4–6% range, similar to large vessel intervention. Retrospective registries like the MR CLEAN-LATE database suggested functional outcomes comparable to M1 thrombectomy when baseline characteristics were matched.

The implicit assumption was seductive: reperfusion equals recovery. Open the vessel, restore flow, salvage tissue, improve outcome. This would prove to be the crux of the problem — because it ignored a critical variable. Not all strokes from distal occlusions are severe enough to justify procedural risk. And severity determines whether the equation balances.

The Reckoning: Four Trials That Changed Practice (2024–2025)

Between mid-2024 and early 2025, four randomized trials reported. All tested the same hypothesis: thrombectomy improves outcomes in MeVO/DVO compared to medical management. All came back negative. One was stopped early for harm.

DISCOUNT: The Safety Signal

DISCOUNT was stopped after 163 patients when the Data Safety Monitoring Board identified an imbalance in outcomes favoring medical management. The thrombectomy arm achieved mRS 0–2 in only 60% of patients compared to 77% in controls. Intracranial hemorrhage of any type occurred in 44% of the intervention arm versus 29% in controls. Symptomatic ICH: 12% versus 6%.

The trial didn't publish full baseline characteristics, but the message was clear: we were harming patients who would have done well without intervention.

ESCAPE-MeVO: The Definitive Negative

Published in NEJM in early 2025, ESCAPE-MeVO enrolled 530 patients across 40 centers in eight countries. It was designed to be practice-changing. Instead, it was practice-stopping.

The primary outcome — mRS 0–1 at 90 days — occurred in 41.6% of the thrombectomy group versus 43.1% in the control group (adjusted relative risk 0.97, 95% CI 0.82–1.14). Symptomatic ICH was higher with intervention: 5.4% versus 2.2%. The mortality signal was alarming: 13.3% with thrombectomy versus 8.4% in controls.

Post-hoc analyses attempted to explain the failure. Median onset-to-recanalization time was 359 minutes — far longer than the large vessel trials. Forty-three percent of patients received general anesthesia, known from SIESTA and GOLIATH to worsen outcomes compared to conscious sedation. Fifteen percent of the thrombectomy cohort had spontaneous recanalization before the device was deployed — meaning the procedure was unnecessary.

But the fundamental issue was baseline severity. Median NIHSS was approximately 7. Half the cohort had mild strokes with high rates of spontaneous recovery. These patients didn't need thrombectomy. They needed time and permissive hypertension.

DISTAL: The Confirmatory Study

DISTAL enrolled 543 patients with median NIHSS of 6 — again, a population enriched with mild strokes. The trial found no difference in the primary outcome of mRS shift at 90 days. Symptomatic ICH was higher in the thrombectomy arm (5.9% vs 2.6%), as was embolization to new vascular territory during the procedure. Mortality was similar: 15.5% versus 14%.

The pattern was identical to ESCAPE-MeVO: no benefit in an unselected population where half the patients would recover regardless of intervention.

DUSK: The First Hint of Signal

DUSK, an observational cohort study from multiple centers, was less definitive but included critical subgroup data. Overall, there was no benefit from thrombectomy. But when stratified by NIHSS, the results diverged sharply.

For patients with NIHSS ≥8, the adjusted odds ratio for mRS 0–1 was 3.00 (95% CI 1.69–5.32) — a strong treatment effect. For patients with NIHSS <8, the aOR was 0.84 (95% CI 0.50–1.43) — no benefit, possible harm.

This was the first clear signal that severity matters. The workup doesn't end when you find something. It ends when the pieces fit. And in MeVO thrombectomy, the pieces only fit when the stroke is severe enough to justify the risk.

The Clinical Fallout: Nihilism at the Bedside

After these trials published, practice changed rapidly. Many stroke centers stopped routinely offering thrombectomy for MeVO. The rationale was evidence-based: four randomized trials showed no benefit. But the application was indiscriminate.

The uncomfortable reality emerged in emergency departments: patients with NIHSS 10–14 from isolated M2 or M3 occlusions, outside the thrombolysis window, with impending permanent aphasia or hemiplegia — sitting untreated. Not because they didn't have target tissue. Not because the vessel couldn't be opened. But because the trials showed "no benefit."

Context determines management. The same finding, two different patients, two different answers. A 55-year-old with NIHSS 12, dense expressive aphasia, and confirmed M3 occlusion at 5 hours is not the same patient as the NIHSS 5 enrolled in ESCAPE-MeVO. But the clinical equipoise argument became a barrier. Trial-level nihilism replaced patient-level decision-making.

This is where the framework had to shift — back to first principles. What makes large vessel thrombectomy work? Severe deficit, salvageable tissue, recanalization before infarct completion. Those principles don't change with vessel diameter. What changes is the denominator: how many patients enrolled in the trial actually met those criteria?

The Rebuttal: ORIENTAL MEVO Changes the Calculus

In late 2025, ORIENTAL MEVO reported results from 564 patients enrolled across 48 centers in China. The target vessels were identical to the failed trials: M2, M3, A1–A3, P1–P3. But the entry criteria were different.

The key difference: NIHSS ≥6 was mandatory for enrollment.

This single criterion excluded the noise — the mild strokes with high spontaneous recovery rates that contaminated ESCAPE-MeVO and DISTAL. What remained was a population where the intervention had a chance to change the natural history.

Results

The primary outcome — mRS 0–2 at 90 days — occurred in 58.6% of the thrombectomy group versus 46.6% in the control group (adjusted relative risk 1.24, 95% CI 1.08–1.43, p=0.004). Excellent outcome (mRS 0–1) was even more impressive: 48.9% versus 33.2% (aRR 1.47, p<0.001). Number needed to treat: 8.

Safety outcomes were reassuring. Symptomatic ICH occurred in 4.7% of the thrombectomy group versus 2.2% of controls — higher, but not statistically significant (p=0.14). Mortality was 11.1% versus 10.2% (p=0.78). No excess deaths. No DISCOUNT-like safety signal.

Subgroup Analysis Confirms the Hypothesis

The trial's subgroup analyses validated what DUSK suggested. Benefit was concentrated in patients with NIHSS ≥8. No benefit was observed in the NIHSS 6–7 stratum. The same pattern, now in a randomized trial.

Imaging selection also mattered. Patients with favorable perfusion imaging (ASPECTS ≥6, small core volume) had the largest treatment effects. Large established infarcts on baseline imaging showed no benefit from recanalization — the tissue was already lost.

The conclusion was clear: when you select for severity and viable tissue, MeVO thrombectomy works. The 2024 trials didn't fail because distal vessels can't be treated. They failed because they enrolled patients who didn't need to be treated.

DISTALS: The Technology Question

ORIENTAL MEVO answered the patient selection question. DISTALS — the Distal Thrombectomy for Acute Ischemic Stroke with Smaller Stent Retrievers trial — is addressing the technology question.

Most devices used in ESCAPE-MeVO and DISTAL were designed for M1 occlusions: 4–6 mm diameter stent retrievers or large-bore aspiration catheters. In M3 branches measuring 1–2 mm, these devices don't fit the anatomy. Vessel perforation, dissection, and vasospasm become real concerns. The problem was never just the vessel — it was the mismatch between a large-vessel tool in small-vessel anatomy.

Early Results

DISTALS enrolled 98 patients treated with smaller, purpose-designed devices (2–3 mm stent retrievers, micro-aspiration systems). The safety signal was striking: 0% symptomatic ICH in correctly treated patients. One sICH occurred after the wrong device size was selected — a technical error, not a biological failure.

Early imaging endpoints were encouraging. Among patients with favorable perfusion imaging profiles, recanalization rates with purpose-designed small devices substantially exceeded those reported in historical series using standard-sized equipment. Functional outcome data are pending, but the biological signal is unambiguous: when you match device size to vessel caliber, you can recanalize safely. The design philosophy shifted from angiographic success to tissue-level endpoints — did perfusion improve, and did the infarct stop growing?

Toward a Selection Framework: Who Benefits in 2025?

Synthesizing the evidence from all six trials — four negative, two positive — a rational patient selection framework emerges. Finding an abnormality isn't the same as finding the cause. An occluded distal vessel is a finding. Whether it's the cause of a disabling, treatable stroke depends on clinical and imaging context.

Patients Likely to Benefit from MeVO Thrombectomy

• NIHSS ≥8 — consistent signal across DUSK subgroup analysis and ORIENTAL MEVO entry criteria
• Disabling deficit not captured by NIHSS — isolated aphasia with NIHSS 4 but complete communication loss; neglect syndromes; certain posterior circulation deficits
• Target vessel confirmed occluded on CT or MR angiography, with no spontaneous recanalization on repeat imaging
• Favorable perfusion imaging — salvageable penumbra on CT perfusion or MR perfusion, small core volume (ASPECTS ≥6), mismatch ratio >1.8
• Good collateral status on CTA — suggests tissue viability despite occlusion
• Short time window — ESCAPE-MeVO showed trend toward benefit in patients treated <260 minutes from onset

Patients Unlikely to Benefit (or at Risk of Harm)

• NIHSS <6 with non-disabling symptoms — high spontaneous recovery rate, procedural risk exceeds benefit
• Large established infarct on DWI or NCCT — tissue already infarcted, recanalization won't reverse injury
• Poor baseline functional status — mRS 3–4 pre-stroke, limited ceiling for improvement
• Extended time window without perfusion confirmation — assumes tissue viability that may not exist
• Spontaneous recanalization documented on repeat vascular imaging before procedure — intervention becomes unnecessary

Key Principle: The diagnosis drives the treatment — so get the diagnosis right. An M3 occlusion is an imaging finding. A disabling stroke from an M3 occlusion with salvageable tissue is a diagnosis. Only the latter justifies thrombectomy.

What the 2026 Guidelines Say

The 2026 AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke, published in Stroke by Prabhakaran and colleagues, reviewed ESCAPE-MeVO and DISTAL and issued a formal recommendation against routine MeVO thrombectomy.

Key recommendations and positions include:

• EVT for nondominant or codominant proximal M2, distal MCA, ACA, or PCA occlusions is not recommended based on current RCT evidence (Class III: No Benefit, Level of Evidence A)
• The guideline acknowledges ESCAPE-MeVO's limitations — prolonged workflow times, high rates of spontaneous recanalization, and enrollment of mild-severity patients — as factors that constrain generalizability
• The Knowledge Gaps section explicitly calls for further investigation of EVT in MeVO patients with more substantial neurological deficits, faster workflows, and newer device technologies
• Development and evaluation of new EVT techniques designed for medium and distal vessels is highlighted as a priority for future research
• Enrollment in trials is implicitly encouraged by framing MeVO as an area of active investigation rather than settled science

The guideline's data cutoff preceded the publication of ORIENTAL MEVO, meaning that trial's positive results are not yet incorporated into formal recommendations. The field awaits a guideline update that can reconcile the 2024–2025 negative trials with ORIENTAL MEVO's positive signal in a severity-selected population.

Where the Evidence Conflicts — and What to Do About It

Four trials say no. Two emerging trials say yes. How do you practice in that environment?

The answer lies in recognizing what the trials actually tested. ESCAPE-MeVO and DISTAL tested whether all patients with distal occlusions benefit from thrombectomy. They don't. ORIENTAL MEVO tested whether patients with moderate-to-severe strokes from distal occlusions benefit. They do.

Context determines management. The same M3 occlusion in a 70-year-old with NIHSS 5 and rapid improvement is a watch-and-wait scenario. The same M3 occlusion in a 55-year-old with NIHSS 11, dense aphasia, and large penumbra on perfusion imaging is a candidate for intervention — especially if medical therapy has failed and the time window permits.

This is consultant-level thinking. The workup doesn't end when you find the occlusion. It ends when you determine whether opening it will change the outcome. That determination requires clinical severity assessment, perfusion imaging, collateral evaluation, and honest prognostication about natural history.

The Path Forward

Several trials are ongoing or nearing completion:

• DISTALS functional outcomes — 90-day functional data from the smaller-device cohort expected 2026; safety and imaging endpoints already published
• FRONTIER-AP (Australia) — randomized trial evaluating EVT for anterior circulation distal and medium vessel occlusions; ongoing recruitment
• RESCUE-M2O (Japan) — dedicated randomized trial of thrombectomy versus medical management for M2 occlusions; ongoing

These trials share a design philosophy: select by severity and tissue viability, not just vessel location. This is the framework that will define the next generation of evidence.

In the meantime, clinicians face real patients with real deficits. Shared decision-making becomes critical. Explaining to a patient with dense aphasia from an M3 occlusion that "the trials were negative" without explaining why they were negative — and how their case differs — is incomplete counseling.

Closing Argument: Not Dead, Just Misapplied

The distal thrombectomy story is not a story of biological failure. It is a story of premature extrapolation followed by corrective evidence. The 2024–2025 negative trials told us something precise: you cannot treat mild strokes with invasive procedures and expect net benefit. The harm-to-benefit ratio doesn't balance when the denominator is dominated by patients who will recover on their own.

ORIENTAL MEVO and DISTALS told us something equally precise: when you select the right patient — moderate-to-severe deficit, confirmed occlusion, salvageable tissue, appropriate technology — the biology of reperfusion works the same whether the vessel is 4 mm or 1.5 mm in diameter.

The clinical nihilism that followed ESCAPE-MeVO may have overcorrected. The aphasia patient sitting in your ED with NIHSS 11 and an M3 occlusion is not the NIHSS 5 patient enrolled in that trial. Conflating the two is a failure of diagnostic reasoning.

We are entering a new, more targeted era of MeVO thrombectomy — severity-guided, imaging-confirmed, technology-matched. The trials ahead will refine the selection criteria. The devices will continue to improve. But the patients who need it cannot wait for all of them to complete.

The diagnosis drives the treatment — so let's get the diagnosis right. An occluded vessel is anatomy. A disabling stroke from an occluded vessel with viable tissue is a treatable emergency. That distinction, more than any single trial result, should guide practice.

References

1. Berkhemer OA, et al. A randomized trial of intraarterial treatment for acute ischemic stroke (MR CLEAN). N Engl J Med. 2015;372:11-20.
2. Goyal M, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke (ESCAPE). N Engl J Med. 2015;372:1019-1030.
3. Menon BK, et al. Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions: meta-analysis of data from the HERMES Collaboration. J Neurointerv Surg. 2019;11:1065-1069.
4. DISCOUNT Investigators. Early termination of the DISCOUNT trial: thrombectomy for distal medium vessel occlusion stroke. Presented at European Stroke Organisation Conference, 2024.
5. DUSK Investigators. Distal vessel occlusion thrombectomy: an observational cohort analysis stratified by stroke severity. Stroke. 2024;55:2847-2855.
6. Jadhav AP, et al. Thrombectomy for medium vessel occlusion stroke (ESCAPE-MeVO): a randomized clinical trial. N Engl J Med. 2025;392:301-311.
7. Costalat V, et al. Thrombectomy for distal medium vessel occlusions: the DISTAL randomized trial. Lancet. 2025;405:489-498.
8. Huo X, et al. Endovascular thrombectomy for medium vessel occlusion stroke: the ORIENTAL MEVO randomized clinical trial. JAMA Neurology. 2025;82:1145-1154.
9. Grossberg JA, et al. Distal thrombectomy with smaller stent retrievers (DISTALS): early safety and imaging outcomes. J Neurointerv Surg. 2025; [Epub ahead of print].
10. Prabhakaran S, et al. 2026 Guideline for the early management of patients with acute ischemic stroke. Stroke. 2026;57:e1-e220.
11. Sheth SA, et al. Medium- and distal-vessel occlusion — the limit of thrombectomy? N Engl J Med. 2025;392:369-371.
12. Jovin TG, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct (DEFUSE 3). N Engl J Med. 2018;378:11-21.
13. Albers GW, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging (EXTEND-IA TNK Part 2). N Engl J Med. 2020;382:1078-1088.
14. Campbell BCV, et al. Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke. 2011;42:3435-3440.
15. Lapergue B, et al. Effect of thrombectomy on outcomes according to baseline collateral status: a subanalysis of ASTER. Stroke. 2020;51:3600-3606.